Ireland-based Endo International plc (OTC:ENDPQ), a specialty pharmaceutical company, announced on Monday that one of its operating companies, Par Pharmaceutical, Inc, has commenced shipping of the authorised generic (AG) version of Merck's Noxafil (posaconazole) 200mg/5mL oral suspension in the United States.
Endo Ventures Limited, a subsidiary of Endo, has signed an exclusive US supply and distribution agreement with a subsidiary of Merck & Co., Inc. of Rahway, New Jersey. The distribution agreement is intended to enable Par Pharmaceutical to introduce and distribute an authorised generic version of the product. The contract also included the authorised generic version of Noxafil delayed-release tablets, 100 mg, which was launched in 2019.
The product is a registered trademark of Merck Sharp & Dohme LLC.
Sandoz to invest USD90m in Biosimilar Technical Development Center in Slovenia
Brenzavvy Now Available for the Treatment of Adults with Type 2 Diabetes
Dr. Reddy's Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
Dr. Reddy's rituximab biosimilar candidate undergoes regulatory review in the US, EU and UK
Grossman Named President and Chief Medical Officer at Coya Therapeutics
Endo International launches first generic version of Merck's Noxafil
Global Pharmaceutical CDMO Market to Reach USD 232.587 bn by 2030, According to Research and Markets
Amneal Releases 2022 Environmental, Social and Governance Report
Oliva Therapeutics Forges Long-Term Partnership with Rio Biopharmaceuticals